16282370	Disease	Gene	D011471	367	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ ? [SEP] Stress kinase signaling regulates @GeneOrGeneProductTgt$ androgen receptor @/GeneOrGeneProductTgt$ phosphorylation , transcription , and localization . Activation of signal transduction kinase cascades is known to alter @GeneOrGeneProductTgt$ androgen receptor @/GeneOrGeneProductTgt$ ( @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ ) activity , but the molecular mechanisms are still poorly defined . Here we show that stress kinase signaling regulates Ser 650 phosphorylation and @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ nuclear export . In LNCaP @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ cells , activation of either MAPK kinase ( MKK ) 4:c-Jun N-terminal kinase ( JNK ) or MKK6:p38 signaling pathways increased Ser 650 phosphorylation , whereas pharmacologic inhibition of JNK or p38 signaling led to a reduction of @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ Ser 650 phosphorylation . Both p38alpha and JNK1 phosphorylated Ser 650 in vitro . Small interfering RNA-mediated knockdown of either MKK4 or MKK6 increased endogenous prostate-specific antigen ( PSA ) transcript levels , and this increase was blocked by either bicalutamide or @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ small interfering RNA . Stress kinase inhibition of PSA transcription is , therefore , dependent on the @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ . Similar experiments involving either activation or inhibition of MAPK/ERK kinase : ERK signaling had little effect on Ser 650 phosphorylation or PSA mRNA levels . Ser 650 is proximal to the DNA binding domain that contains a nuclear export signal . Mutation of Ser 650 to alanine reduced nuclear export of the @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ , whereas mutation of Ser 650 to the phosphomimetic amino acid aspartate restored @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ nuclear export . Pharmacologic inhibition of stress kinase signaling reduced wild-type @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ nuclear export equivalent to the S650A mutant without affecting nuclear export of the S650D mutant . Our data suggest that stress kinase signaling and nuclear export regulate @GeneOrGeneProductTgt$ AR @/GeneOrGeneProductTgt$ transcriptional activity .	3 3 4 4 8|4 8|4 8 8|4 4 8 8 8 8 8 4 23 21 21 21 21 16 23 23 25 23 33|25|26 33|25|26 33|26 33|25|26 30 33|27 33 33|27 30 25 23 23 38 38 42 42 42 42 23 23 48 48 48 53 52 52 53 48 56 56 53 56 61|57 61 61|57 61 56 48 69 69 65|69 65|69 69 65|69 89 89 89 77 75 75 77 77 71 77 81 81 77 83 81 83 77 88 88 77 89 92 92 89 89 89 96 102 98 96 98 98 98 89 105 105 102 111 111|104 111 111|104 111 111 105 89 116 119 116 116 119 119 123 123 119 119 126 134 128 126 131 131 128 131 131 134 137 137 142 139 142 142 142 134 134 134 146 148 148 134 151 151 148 151 156|152 156 156|152 156 151 151 134 161 162 170 165 165 162 170 170 170 170 170 173 173 170|172 170 170|172 170 178 190 178 181 179 181 181 186 186 183 178 189 190 190 192 190 196 196 196 192 196 199 200 196 190 205 202 205 205 210 210 210 210 205 212 210 216 216 216 212 205 224 220 218 220 223 218 224 226 224 229 229 226|228 226 226|228 224 243 243 235 233 235 242 242 242 242 242 233 224 242|247 247 242|247 247 243 224 252 257 256 256 256 252 257 263 258|262 262 258|262 262 263 257 267 267 267 263 269 257 271 269 275 275 275 271 257 279 280 280 288 284 284 288 284 287 284 280 288|292 292 288|292 292 288 280	Association
18565893	Disease	Gene	D008545	472	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ melanoma @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ ? [SEP] Risk of cancer by @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for @DiseaseOrPhenotypicFeatureSrc$ melanoma @/DiseaseOrPhenotypicFeatureSrc$ , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 166|161 161 166|161 168 175 174 174 175 168 175 179 179 175 175 183 183 175 183 183 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
18565893	Disease	Gene	D001943	472	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ ? [SEP] Risk of cancer by @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations do not increase the risk of cancer overall or of @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ in the general population ; however , we observed in exploratory analyses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 72 69|72 69|72 69|72 69|72 64 64 81 81 81 81 64 85 85 85 81 52 90 90 90 95 95 90 97 95 102 102 102 102 97 105 105 97 105 109 109 105 95 112 114 114 95 114 95 135 117 120 117 122 120 127 127|123 127 127|123 127 122 127 127 135 135 134 134 131 135 139 139 139 135 139 142 149 149 149 149 149 148 149 117 149 153 153 149 153 156 156|153|154 156|153|154 156|153 156|153|154 156 164 163 163 164 135 164 168 168 164 168 171 164 171 177 176 176 177 171 177 181 181 177 177 185 185 177 185 185 192 191 191 192 171 192 196 196 192 196 199 171 203 203 203 199 135 208 208 210 208 215 215|211 215 215|211 215 210 215 215 223 223 222 222 223 208 227 227 227 223 227 230 237 237 237 237 237 236 237 208 241 241 241 237 241 244 242|244|237 242|244|237 244|237 242|244|237 244 252 251 251 252 237 252 256 256 252 256 261 261 261 256 256 252 268 267 267 268 252 268 272 272 268 272 275 268 278 278 275 208 282 290 283|287 287 283|287 287 290 290 290 282 292 290 294 292 290 295 298 298|295|296 298|295|296 298|295 298|295|296 304 304 304 290 290 309 309 309 290 312 312 309 320 317|310 317 317|310 317 320 320 320 309 324 324 324 320 328 328 328 324 282 335 335 344 337 335 344 344 342 342 339 344 344 346 344 346 347 350 346 344	Association
18565893	Disease	Gene	D011471	472	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ ? [SEP] Risk of cancer by @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 161 168 174 173 173 174 168 174 178 178 174 174 181 179|181|174 179|181|174 181|174 179|181|174 181 181 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
16835864	Disease	Gene	D011471	11200	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ ? [SEP] Characterization of @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations in @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ . The @GeneOrGeneProductTgt$ checkpoint kinase 2 @/GeneOrGeneProductTgt$ ( @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ , also known as @GeneOrGeneProductTgt$ CHK2 @/GeneOrGeneProductTgt$ ) is a tumor suppressor that participates in the DNA damage-signaling pathway . It is phosphorylated and activated following DNA damage , resulting in cell cycle arrest and apoptosis . Previously , we reported germline @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations in patients with @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ . In this study , we have identified two novel somatic @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations , c.349A > G ( p. R117 G ) and c.967A > C ( p. E321 K ) , in @DiseaseOrPhenotypicFeatureSrc$ prostate tumor @/DiseaseOrPhenotypicFeatureSrc$ specimens and investigated the functions of these mutants in vivo . We have shown that most of the germline @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations and one somatic mutation ( p. R117 G ) within FHA domain have modestly reduced @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ kinase activity in comparison with wild-type @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ while the other somatic mutation ( p. E321 K ) within the kinase domain of @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ totally abolished @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ kinase activity . Given that several clinical @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations reside in the Forkhead-associated ( FHA ) domain , we further generated a series of missense mutations within this domain and demonstrated the requirement of an intact FHA domain for the full activation of @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ . Taken together , these results provide evidence that both germline and somatic @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ mutations identified in @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ may contribute to the development of @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ through the reduction of @GeneOrGeneProductTgt$ CHEK2 @/GeneOrGeneProductTgt$ activation in response to DNA damage and/or oncogenic stress .	1 5 2|5 5 2|5 1 7 1|5|7 1|5|7 1|7 1|5|7 1 14 13|14|31 13|14|31 13|14|31 14|31 13|14|31 19 14|15 14 14|15 19 23 14 25 20|23 23 20|23 14 31 31 31 31 33 31 38 38 38 38 33 31 45 45 45 45 45 50 50 47 45 45 56 56 56 52 56 56 45 63 63 63 63 67 67|64 67 67|64 63 69 67 71 69|71 69|71 69|71 69|71 63 79 79 83 83 83 83 83 89 89 89 86|89 89 86|89 83 83 83 91 92 97 97 97 93 97 91 91 106 106 106 106 106 100 106 91 113 108|113 108|113 113 108|113 91 83 83 117 115 120 120 117 122 115 83 128 128 128 151 151 136 136 136 133|136 136 133|136 130 130 140 140 130 144 144 144 140 144 148 148 140 151 151 128 150|155 155 150|155 155 151 157 151 160 160 157 157 157 180 166 166 166 180 170 170 170 166 170 175 175 175 166 177 173|175 175 173|175 180 151 184|176 184 184|176 184 180 128 198 198 197 197 194|197 197 194|197 198 209 205 205 205 205 205 205 198 209 209 209 209 211 209 214 214 211 217 217 211 209 209 221 219 226 226 226 226 221 230 230 230 221 232 230 230 230 209 242 237 242 241 242 242 242 252 246 252 246 251 248|251 251 248|251 246 243 254 252|254 252|254 252|254 252|254 258 242 261 261 258 263 261|263|259 261|263|259 261|263 261|263|259 268 268 261 272 264|272 272 264|272 268 274 268 277 277 274 277 280 277 242	Association
17487399	Disease	Gene	D030321	7490	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ Denys-Drash syndrome @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ transcriptional target genes in prostate cancer cells , we have established stably transfected LNCaP cell lines expressing either @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ likely contributes to kidney angiogenesis during development and @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ mutants such as DDS(R384W ) are associated with the @DiseaseOrPhenotypicFeatureSrc$ Denys-Drash syndrome @/DiseaseOrPhenotypicFeatureSrc$ ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP prostate cancer cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneOrGeneProductTgt$ DDS-WT1 @/GeneOrGeneProductTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneOrGeneProductTgt$ DDS-WT1 @/GeneOrGeneProductTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP prostate cancer cells . However our observations are also consistent with wild-type @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 36 23 28 28|23 28 28|23 28 28 21 32 32 32 28 36 36 36 36 38 41 41 41 36 41 44 42 42 42 41 36 51 51 51 36 51 36 36 56 36 36 61 65 64 64 61 65 76 70 70 70 76 72 70 72 76 76 65 80 80 80 76 65 89 84 82 86 82|85 82 82|85 89 89 92 92 89 94 92 94 94 94 94 94 101 99 98 98 104 89 107 107 107|104 107|104 107|104 107|104 111 107 111 107 107 117 117 114 89 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 187 187 179 162 190 195 193 193 190 195 195 199 199 199 195 208 208 204 204 201 207 207 201 199 212 212 212 208 216 216 216 212 216 216 195 222 222 226 225 225 222 226 230 227|230 230 227|230 226 232 230 236 236 236 230 239 239 236 226 243 245 245 245 247 245 250 250 247 253 253 250 256 256 253 256 245 260 245 262 263 260 267 267 267 260 245 271 271 281 273 271|272 271 271|272 273 273 273 273 273 281 281 286 286 286 286 281 281 291 291 291 281 296 294 296 296 291 281 300 301 301 306 306|302 306 306|302 306 301 308 306 310 308 308 308 314 312 319 319 319 319 312 301 327 324 327 327 327 327 330 330 329|327 327 329|327 330 327 335 338 335 335 333 342 341 342 338 345 345 333 347 345 327 351 363 354 354 351 356 351|355 351 351|355 356 356 361 359 351 363 366 366 363 368 366 366 366 375 372 375 372 372 366 363	Association
17487399	Disease	Gene	D011471	7490	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ transcriptional target genes in @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ cells , we have established stably transfected LNCaP cell lines expressing either @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ likely contributes to kidney angiogenesis during development and @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ mutants such as DDS(R384W ) are associated with the Denys-Drash syndrome ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneOrGeneProductTgt$ DDS-WT1 @/GeneOrGeneProductTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneOrGeneProductTgt$ DDS-WT1 @/GeneOrGeneProductTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ cells . However our observations are also consistent with wild-type @GeneOrGeneProductTgt$ WT1(A @/GeneOrGeneProductTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneOrGeneProductTgt$ WT1 @/GeneOrGeneProductTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 37 23 28 28|23 28 28|23 28 28 21 33 28|33 28|33 33 28|33 28 37 37 37 37 39 42 42 42 37 42 45 43|41 43 43|41 42 37 52 52 52 37 52 37 37 57 37 37 63 67 66 66 63 67 78 72 72 72 78 74 72 74 78 78 67 82 82 82 78 67 91 86 84 88 84|87 84 84|87 91 91 94 94 91 96 94 96 96 96 96 96 103 101 100 100 106 91 110 110 110 106 112 110 112 110 110 118 118 115 91 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 184|188 184|188 188 184|188 179 162 192 197 195 195 192 197 197 201 201 201 197 210 210 206 206 203 209 209 203 201 214 214 214 210 218 218 218 214 218 218 197 224 224 228 227 227 224 228 232 229|232 232 229|232 228 234 232 238 238 238 232 241 241 238 228 245 247 247 247 249 247 252 252 249 255 255 252 258 258 255 258 247 262 247 264 265 262 269 269 269 262 247 273 273 283 275 273|274 273 273|274 275 275 275 275 275 283 283 288 288 288 288 283 283 293 293 293 283 298 296 298 298 293 283 302 303 303 308 308|304 308 308|304 308 303 310 308 312 310 310 310 316 314 322 322 317|322 317|322 322 317|322 314 303 331 328 331 331 331 331 334 334 333|331 331 333|331 334 331 339 342 339 339 337 346 345 346 342 349 349 337 351 349 331 355 367 358 358 355 360 355|359 355 355|359 360 360 365 363 355 367 370 370 367 372 370 370 370 379 376 379 376 376 370 367	Association
15146458	Disease	Gene	D011471	23520	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ ? [SEP] Identification of a functional mutation in @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ ( @GeneOrGeneProductTgt$ ANP32C @/GeneOrGeneProductTgt$ ) . No mutations or polymorphisms have previously been reported in @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ ( @GeneOrGeneProductTgt$ ANP32C @/GeneOrGeneProductTgt$ ; GenBank : AF008216.1 ) . @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ is part of the highly conserved ANP32 family , some of whose members are associated with control of histone acetylation , mRNA stability , and specialized forms of apoptosis . Although 87.6 % identical at the protein level , @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ is functionally distinct from pp32 ( ANP32A ) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays . The present study found that @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ expression levels vary among human tumor cell lines , with the highest levels found in @DiseaseOrPhenotypicFeatureSrc$ prostatic adenocarcinoma @/DiseaseOrPhenotypicFeatureSrc$ cell lines . @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions , human fibroblast cell lines , and several carcinoma cell lines . PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci , but additionally contain a g.4870T > C transversion mutation . The mutation results in a p. Tyr140His substitution , which lies in a functionally important region of the molecule . In the PC-3 @DiseaseOrPhenotypicFeatureSrc$ prostate cancer @/DiseaseOrPhenotypicFeatureSrc$ line , the mutation is either homozygous , or hemizygous accompanied by loss of heterozygosity . ACHN cells stably transfected with @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ containing this mutation showed a markedly increased rate of growth . The @GeneOrGeneProductTgt$ pp32r1 @/GeneOrGeneProductTgt$ mutation could thus be causally associated with the neoplastic growth properties of PC-3 , and be of potential clinical significance .	1 5 5 5 1 7 5|6 5 5|6 10 8|7 7 8|7 10 1 17 23 17 17 23 23 23 23 28 24|28 28 24|28 28 23|26 23 23|26 28 28 31 31 28 23 37|41 41 37|41 41 41 47 47 45 47 47 41 47 54 54 52 54 54 41 56 54 59 59 56 59 62 59 54 54 66 54 68 66 41 74 73 74 84 78 78 78 74 84 79|84 84 79|84 84 84 84 86 84 88 86 88 92 92 84 94 92 94 100 100 97 100 95 92 103 92 107 107 105 103 84 112 112 113 113 119 118|114 118 118|114 118 119 113 124 124 124 124 119 124 129 129 129 124 129 136 136|130 136|130 136 136|130 136 130 113 139|143 143 139|143 143 143 146 146 143 149 149 146 149 152 149 158 158 158 158 158 149 143 163 163 163 143 163 143 169 169 169 143 143 176 176 176 176 178 178 178 181 181 178 184 184 181 178 178 188 178 190 188 190 194 194 190 178 197 198 198 203 203 203 201 198 203 206 203 211 211 210 211 206 214 214 211 198 222 222 222 218|222 218|222 222 218|222 228 222 225 228 228 228 228 228 228 228 228 234 232 236 234 228 240 249 242 240 244 242|243 242 242|243 244 248 246 249 253 252 253 249 255 253 249 261 258|261 261 258|261 266 266 266 266 266 266 271 271 271 271 266 273 271 266 266 280 280 280 280 266 266	Association
12917204	Disease	Gene	D001943	472	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ ? [SEP] The relationship between twenty missense @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ variants and @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ risk : the Multiethnic Cohort . Deficiencies in tasks of detecting and repairing DNA damage lead to mutations and chromosomal abnormalities , a hallmark of cancer . The gene mutated in ataxia-telangiectasia ( A-T ) , @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ , is a proximal component in performing such tasks . Studies of A-T families have suggested an increased risk of @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ among obligate female heterozygous carriers of @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ mutations . Paradoxically , studies of sporadic and @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ have failed to demonstrate an elevated prevalence of mutations among @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases . We characterized the prevalence and distribution of 20 @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations/polymorphisms in a population-based case-control study of 854 African-American , Latina , Japanese , and Caucasian women aged > /== " BORDER="0">45 years participating in the Multiethnic Cohort Study . The study population included 428 incident @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and 426 controls . The prevalence of variants ranged from 0 % to 13.6 % among controls and varied by ethnicity ( 0 - 32.5 % ) . Overall , these data provide little support for an association of @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations with @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ among older women . We observed only one sequence variation ( L546V ) , common among African-American women , to be overrepresented among all high-stage @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases ( odds ratio , 3.35 ; 95 % confidence interval , 1.27 - 8.84 ) . After correction for multiple comparisons , this observed risk modification did not attain statistical significance . The distribution of @GeneOrGeneProductTgt$ ATM @/GeneOrGeneProductTgt$ missense mutations and polymorphisms varied widely across the four ethnic groups studied . Although a single missense variant ( L546V ) appeared to act as a modest predictor of risk , the remaining variants were no more common in @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases as compared with controls .	2 2 8 8 8 8|5 8 8|5 2 8 8|10|13 8|10|13 10|13 8|10|13 8 8 17 17 8 2 30 23 21 25 23 25 25 29 25 30 32 30 32 35 32 35 38 35 40 38 30 43 57 43 46 44 48 46 48 46 50|46 46 50|46 43 57 57 57 57 59 57 61 59 57 69 67 67 64 69 69 72 72 69 74 72|73|74 72|73|74 72|74 72|73|74 81 81 81 81 72 85 80|85 85 80|85 81 69 100 100 100 93 95 93 91|93|94|95 91|93|94|95 91|93|94|95 91|93|95 91|93|94|95 100 100 102 100 105 105 102 107 105 112 112|105 112|105 112 112|105 107 100 117 117 119 117 119 119 127 127 123|127 127 123|127 127 119 132 132 132 132 119 143 143 143 135 135 137 137 139 139 139 132 143 146 149 148 149 144 149 155 155 155 155 150 117 160 160 161 161 167 167 167|163 167|163 167 167|163 161 167 170 167 161 174 177 176 174 177 180 180 177 183 183 177 185 177 177 177 189 187 194 193 193 194 189 194 177 201 201 200 201 201 203 201 206 206 203 211 207|211 211 207|211 211 206 213 213|206|211 213|206|211 213|206 213|206|211 218 218 206 201 223 223 225 227 227 223 229 227 229 227 227 235 235 232 227 239 239 227 246 246 246 246|242 246|242 246 246|242 239 249 249 246 249 249 249 256 256 256 249 256 260 260 256 249 223 265 271 268 268 265 271 271 271 273 276 276 276 271 278 276 271 281 289 286 282|286 286 282|286 286 281 286 286 289 289 295 295 295 295 289 295 289 307 303 303 303 307 305 303 305 323 309 307 313 313 313 309 315 313 323 319 319 323 323 323 323 323 328 324|328 324|328 328 324|328 323 330 323 332 330 323	Association
12872252	Disease	Gene	D010051	59348	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast and ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes @GeneOrGeneProductTgt$ ZNF350/ZBRK1 @/GeneOrGeneProductTgt$ and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ families and among early-onset breast cancer cases and reference individuals . Two potential breast cancer susceptibility genes , encoding the BRCA1-interacting proteins @GeneOrGeneProductTgt$ ZNF350 @/GeneOrGeneProductTgt$ ( or @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ ) and BRIP1 ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of @DiseaseOrPhenotypicFeatureSrc$ ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ , or three or more cases of @DiseaseOrPhenotypicFeatureSrc$ breast and ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ . In addition , 58 early-onset ( before age 35 ) breast cancer cases and 30 reference individuals were analyzed . Of 17 variants detected in @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in BRIP1 , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with breast cancer . Haplotype analysis suggests that all @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the BRIP1 SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 6 6 7 7 12 7 12 15 12 20 20|15 20|15 20 20|15 2 20 26 26 26 26 20 26 29 26 2 38 38 38 38 38 60 38 38 43 43 44 40|43 40 40|43 48 46 44|46 44 44|46 48 44 44 52 52 52 52 44 60 60 60 64 64 64 60 60 69 69 71 69 73 71 76 76 73 81 79 81 81 76 87 87 85 83 87 69 90 90 87 87 93 93 95 96 97 93 101 101 101 97 97 104 97 106 104|105|106 104|105|106 104|106 104|105|106 106 106 114 111 111 106 116 116|113|114 116|113|114 116|113|114 116|113|114 116|114 116|113|114 93 125 142 142 128 142 136 131 129 136 136 136 136 128 128 140 140 142 142 142 142 145 146 157 146 149 147|148 147 147|148 149 155 155 155 149 157 157 160 160 157 164 164 164 160 157 157 170 170 170 172 172 157 174 172 172 178 179 195 179 182 180 179 185 189 189 189 189 179 189 189 189 195 195 195 195 196 202 202 202 202 196 196 208 208 208 208 196 212 212 212 208 195 195 216 219 219 219 195 223 223 223 219 226 226 223 195 229 230 230 236 235 235|232 235 235|232 236 230 240 240 240 236 243 243 240 243 246 244 250 250 250 246 236 256 255 255 256 236 259 259 256 236 263 263 236 263 266 264 270 270 270 266 230 292 275 273 277 275|276 275 275|276 277 277 284 284 284 275 289 289 289 289 284 292 292 292 292 299 299 298 298 295 293 303 303 303 299 307 307 307 303 292 311 317 314 314 311 317 317 317 319 317 324 323 323 324 319 326 324 329 329 324 332 332 329 336 336 336 329 317 339 340 340 340 340 342 340 340 350 350 350 350 350	Association
12872252	Disease	Gene	D001943	59348	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes @GeneOrGeneProductTgt$ ZNF350/ZBRK1 @/GeneOrGeneProductTgt$ and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and reference individuals . Two potential @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ susceptibility genes , encoding the BRCA1-interacting proteins @GeneOrGeneProductTgt$ ZNF350 @/GeneOrGeneProductTgt$ ( or @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ ) and BRIP1 ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of ovarian cancer , or three or more cases of breast and ovarian cancer . In addition , 58 early-onset ( before age 35 ) @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and 30 reference individuals were analyzed . Of 17 variants detected in @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in BRIP1 , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . Haplotype analysis suggests that all @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the BRIP1 SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of @GeneOrGeneProductTgt$ ZBRK1 @/GeneOrGeneProductTgt$ and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 6 6 7 7 12 7 12 15 12 19 19 19 2 19 26 26 26|21 26|21 26 26|21 19 26 29 26 2 39 39 34|39 34|39 39 34|39 39 61 39 39 44 44 45 41|42 41 41|42 49 47 45 45 45 49 45 45 53 53 53 53 45 61 61 61 65 65 65 61 61 71 71 73 71 75 73 78 78 75 83 81 83 83 78 89 89 87 85 89 71 92 92 89 89 95 95 97 98 99 95 103 103 103 99 99 106 99 109 109 106 109 109 115 112 112 109 117 115 117 120 117 95 123 141 141 126 141 135 129 127 135 135 131|135 131|135 135 131|135 126 126 139 139 141 141 141 141 145 146 157 146 149 147|148 147 147|148 149 155 155 155 149 157 157 160 160 157 164 164 164 160 157 157 170 170 170 172 172 157 174 172 172 178 179 195 179 182 180 179 185 189 189 189 189 179 189 189 189 195 195 195 195 196 202 202 202 202 196 196 208 208 208 208 196 212 212 212 208 195 195 216 219 219 219 195 223 223 223 219 225 224|225|223 224|225|223 225|223 224|225|223 195 231 232 232 238 237 237|234 237 237|234 238 232 242 242 242 238 245 245 242 245 248 246 252 252 252 248 238 258 257 257 258 238 261 261 258 238 265 265 238 265 268 266 272 272 272 268 232 294 277 275 279 277|278 277 277|278 279 279 286 286 286 277 291 291 291 291 286 294 294 294 294 301 301 300 300 297 295 305 305 305 301 309 309 309 305 294 313 319 316 316 313 319 319 319 321 319 326 325 325 326 321 328 326 331 331 326 333 331|332|333 331|332|333 331|333 331|332|333 339 339 339 331 319 343 344 344 344 344 346 344 344 354 354 354 354 354	Association
12872252	Disease	Gene	D001943	83990	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and @GeneOrGeneProductTgt$ BRIP1/BACH1 @/GeneOrGeneProductTgt$ among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and reference individuals . Two potential @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ susceptibility genes , encoding the BRCA1-interacting proteins ZNF350 ( or ZBRK1 ) and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of ovarian cancer , or three or more cases of breast and ovarian cancer . In addition , 58 early-onset ( before age 35 ) @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and 30 reference individuals were analyzed . Of 17 variants detected in ZBRK1 , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of ZBRK1 and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 7 8|7 7 8|7 12 7 12 15 12 19 19 19 2 19 26 26 26|21 26|21 26 26|21 19 26 29 26 2 39 39 34|39 34|39 39 34|39 39 60 39 39 44 44 45 41 48 46 45 48 45 48|45 45 48|45 51 51 51 51 45 60 60 60 64 64 64 60 60 69 69 71 69 73 71 76 76 73 81 79 81 81 76 87 87 85 83 87 69 90 90 87 87 93 93 95 96 97 93 101 101 101 97 97 104 97 107 107 104 107 107 113 110 110 107 115 113 115 118 115 93 121 139 139 124 139 133 127 125 133 133 129|133 129|133 133 129|133 124 124 137 137 139 139 139 139 143 144 154 144 147 145 147 152 152 152 147 154 154 157 157 154 161 161 161 157 154 154 167 167 167 169 169 154 171 169 169 174 175 192 175 178 176|177 176 176|177 175 182 186 186 186 186 175 186 186 186 192 192 192 192 193 199 199 199 199 193 193 205 205 205 205 193 209 209 209 205 192 192 213 216 216 216 192 220 220 220 216 222 220|222 220|222 220|222 220|222 192 229 230 230 235 234 234 235 230 239 239 239 235 242 242 239 242 245 243 249 249 249 245 235 256 255 252|255 255 252|255 256 235 259 259 256 235 263 263 235 263 266 264 270 270 270 266 230 292 275 273 277 275 277 277|278 277 277|278 284 284 284 275 289 289 289 289 284 292 292 292 292 299 299 298 298 295 293 303 303 303 299 307 307 307 303 292 311 317 314 314 311 317 317 317 319 317 324 323 323 324 319 326 324 329 329 324 331 329|330|331 329|330|331 329|331 329|330|331 337 337 337 329 317 341 342 342 342 342 344 342 342 352 352 352 352 352	Association
12872252	Disease	Gene	D010051	83990	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast and ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and @GeneOrGeneProductTgt$ BRIP1/BACH1 @/GeneOrGeneProductTgt$ among BRCA1 and BRCA2-negative probands from @DiseaseOrPhenotypicFeatureSrc$ breast-ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ families and among early-onset breast cancer cases and reference individuals . Two potential breast cancer susceptibility genes , encoding the BRCA1-interacting proteins ZNF350 ( or ZBRK1 ) and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of @DiseaseOrPhenotypicFeatureSrc$ ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ , or three or more cases of @DiseaseOrPhenotypicFeatureSrc$ breast and ovarian cancer @/DiseaseOrPhenotypicFeatureSrc$ . In addition , 58 early-onset ( before age 35 ) breast cancer cases and 30 reference individuals were analyzed . Of 17 variants detected in ZBRK1 , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with breast cancer . Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of ZBRK1 and @GeneOrGeneProductTgt$ BRIP1 @/GeneOrGeneProductTgt$ in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 7 8|7 7 8|7 12 7 12 15 12 20 20|15 20|15 20 20|15 2 20 26 26 26 26 20 26 29 26 2 38 38 38 38 38 59 38 38 43 43 44 40 47 45 44 47 44 49|44 44 49|44 50 50 50 50 44 59 59 59 63 63 63 59 59 67 67 69 67 71 69 74 74 71 79 77 79 79 74 85 85 83 81 85 67 88 88 85 85 91 91 93 94 95 91 99 99 99 95 95 102 95 104 102|103|104 102|103|104 102|104 102|103|104 104 104 112 109 109 104 114 114|111|112 114|111|112 114|111|112 114|111|112 114|112 114|111|112 91 123 140 140 126 140 134 129 127 134 134 134 134 126 126 138 138 140 140 140 140 143 144 154 144 147 145 147 152 152 152 147 154 154 157 157 154 161 161 161 157 154 154 167 167 167 169 169 154 171 169 169 174 175 192 175 178 176|177 176 176|177 175 182 186 186 186 186 175 186 186 186 192 192 192 192 193 199 199 199 199 193 193 205 205 205 205 193 209 209 209 205 192 192 213 216 216 216 192 220 220 220 216 223 223 220 192 227 228 228 233 232 232 233 228 237 237 237 233 240 240 237 240 243 241 247 247 247 243 233 254 253 250|253 253 250|253 254 233 257 257 254 233 261 261 233 261 264 262 268 268 268 264 228 290 273 271 275 273 275 275|276 275 275|276 282 282 282 273 287 287 287 287 282 290 290 290 290 297 297 296 296 293 291 301 301 301 297 305 305 305 301 290 309 315 312 312 309 315 315 315 317 315 322 321 321 322 317 324 322 327 327 322 330 330 327 334 334 334 327 315 337 338 338 338 338 340 338 338 348 348 348 348 348	Association
12628588	Disease	Gene	D001943	1052	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ C/EBPD @/GeneOrGeneProductTgt$ ? [SEP] Detection of base sequence changes in the @GeneOrGeneProductTgt$ CEBPD @/GeneOrGeneProductTgt$ gene in human @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cell lines and primary @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ isolates . Single strand conformation polymorphism ( SSCP ) analysis was performed on genomic DNA from 97 human @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ samples and 10 breast cell lines to screen for mutations in the single exon @GeneOrGeneProductTgt$ C/EBPD @/GeneOrGeneProductTgt$ gene . Three @GeneOrGeneProductTgt$ C @/GeneOrGeneProductTgt$ -- > T transitions resulting in silent mutations were detected in three individual @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ samples . One @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ sample also contained a G -- > T transversion ( Q253H ) . The SUM-52PE cell line contained an A -- > T transversion ( AAG -- > TAG ) resulting in a nonsense mutation ( K180Stop ) . All mutations identified in genomic DNA isolates were in highly conserved regions of the @GeneOrGeneProductTgt$ C/EBPD @/GeneOrGeneProductTgt$ gene . This study indicates that mutational alterations in the coding region of the @GeneOrGeneProductTgt$ C/EBPD @/GeneOrGeneProductTgt$ gene are relatively uncommon in human @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ .	1 5 5 5 1 10 10 10|7 10 10|7 5 17 17 17|11 17|11 17 17|11 17 10 17 23 16|20|23 16|20|23 20|23 16|20|23 17 1 31 31 31 35 33 35 35 37 37 37 40 40 37 47 47 47 43|47 43|47 47 43|47 37 47 52 52 52 47 54 37 56 54 63 63 63 63 63|58 63 63|58 56 37 68 67|73 73 67|73 73 73 73 79 73 77 77 74 79 79 86 86 86 86|81 86|81 86 86|81 79 79 94 90|94 90|94 94 90|94 96 96 96 98 96 102 102 102 98 104 102 104 96 111 111 111 112 112 114 112 118 118 118 114 120 118 123 123 120 123 118 129 129 129 125 131 129 131 112 135 145 135 140 140 140 136 145 145 144 145 145 150 150 150|147 150 150|147 145 145 154 155 155 170 158 170 162 162 162 158 167 167 164|167 167 164|167 162 170 170 155 173 173 170|171|173 170|171|173 170|173 170|171|173 155	Association
12702523	Disease	Gene	D001943	7157	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ ? [SEP] Prognostic value of @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ molecular status in high-risk primary @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . BACKGROUND : Mutations in the @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ gene are the most common genetic alterations in human primary @DiseaseOrPhenotypicFeatureSrc$ breast carcinoma @/DiseaseOrPhenotypicFeatureSrc$ and these mutations are often associated with worse prognosis and chemo/radioresistance . PATIENTS AND METHODS : The analysis of the @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ gene was performed by fluorescence-assisted mismatch analysis in 13 consecutive high-risk primary @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ ( HR-BC ) patients with 10 or more involved axillary nodes to evaluate its prognostic value . RESULTS : Three @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ mutations ( 23 % ) and four allelic variants were detected . After a median follow-up of 52 months the HR-BC disease-free survival ( DFS ) was 51 % and overall survival 79 % . All patients harboring a @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ mutation ( @GeneOrGeneProductTgt$ p53(mut @/GeneOrGeneProductTgt$ ) ) relapsed within 10 months of the median DFS while 67 % of those showing a wild-type @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ status ( @GeneOrGeneProductTgt$ p53(wt @/GeneOrGeneProductTgt$ ) ) survive disease-free at a median follow-up of 43 months . One @GeneOrGeneProductTgt$ p53(mut @/GeneOrGeneProductTgt$ ) patient is still alive while all the @GeneOrGeneProductTgt$ p53(wt @/GeneOrGeneProductTgt$ ) patients survive at 56 months median follow-up . Two out of the four @GeneOrGeneProductTgt$ p53(wt @/GeneOrGeneProductTgt$ ) relapsing @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ patients showed the Arg72Pro allelic variant ; one of these died at 75 months . CONCLUSIONS : @GeneOrGeneProductTgt$ p53 @/GeneOrGeneProductTgt$ mutations may help identify a subset of very high risk @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ patients ( vHR-BC ) with worse prognosis .	2 2 7 3|7 7 3|7 7 2 11 11 11 9|11|7 9|11|7 11|7 9|11|7 2 17 17 30 24 24 24|21 24 24|21 19 30 30 28 30 30 17 34 34 34 32|34|30 32|34|30 34|30 32|34|30 30 39 42 42 42 30 45 45 42 45 45 17 51 51 51 51 56 63 61 61 58|61 61 58|61 56 63 51 67 67 67 63 79 79 79 79 79 79|71|73 79|71|73 79|73 79|71|73 77 79 79 67 86 86 81 84 81 86 79 88 63 91 91 88 63 95 95 100 97|100 100 97|100 110 103 103 100 103 100 108 108 100 110 95 95 116 116 116 129 119 119 116 123 123 123 129 125 123 125 129 129 129 129 132 129 134 129 129 137 148 137 142 139|142 142 139|142 138 144 137|142 137 137|142 144 144 148 151 151 148 155 155 155 151 172 158 172 160 158 160 166 166 161|166 166 161|166 161 168 164|166 166 164|166 168 168 148 172 177 177 177 172 180 180 177 148 187 186|190 190 186|190 190 193 193 193 193 201 200 200 195|200 200 195|200 200 201 193 204 204 201 206 201 193 223 210 222 222 215 218|214 218 218|214 218 222 217|222 217|222 222 217|222 211 223 227 227 227 223 223 232 231 229 223 235 235 232 223 239 239 240|243 243 240|243 246 246 246 239 248 246 256 251 252 256 256|251 256|251 256 256|251 248 258 256 258 262 262 246 239	Association
11212236	Disease	Gene	D001943	7048	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast tumor @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ ? [SEP] Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . Members of the transforming growth factor beta ( TGF-beta ) family are potent inhibitors of the growth of many epithelial cell types . Transmembrane signaling by TGF-beta occurs via a complex of the serine/threonine kinases TGF-beta type 1 receptor and TGF-beta type 2 receptor ( @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ ) , and inactivating mutations in the latter have recently been detected in some primary tumors and in several types of tumor-derived cell lines . The most common mutations that have been identified in @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ are frameshifts in a repetitive polyadenine region in replication error-positive colorectal carcinomas that result in a truncated protein and absence of receptor expression at the cell surface . A number of point mutations in the highly conserved serine/threonine kinase domain of @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ have also been reported , some of which have been correlated with either loss of trans-phosphorylation of TGF-beta type 1 receptor or constitutive activation of trans-phosphorylation . No @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ mutations have been reported in human @DiseaseOrPhenotypicFeatureSrc$ breast tumors @/DiseaseOrPhenotypicFeatureSrc$ , but anomalous expression of TGF-beta in @DiseaseOrPhenotypicFeatureSrc$ breast carcinomas @/DiseaseOrPhenotypicFeatureSrc$ suggests that TGF-beta signaling may be defective . We have therefore systematically examined unmatched sets of 17 primary and 17 recurrent @DiseaseOrPhenotypicFeatureSrc$ breast tumor @/DiseaseOrPhenotypicFeatureSrc$ samples for mutations in @GeneOrGeneProductTgt$ TGFBR2 @/GeneOrGeneProductTgt$ , restricted to those regions of the gene in which mutations have previously been reported . None of the previously reported mutations was detected , but four novel mutations ( V387 M , N435S , V447A , and L452 M ) were found in the kinase domain in recurrent tumors . No mutations were detected in primary tumors . TGF-beta signaling was significantly inhibited by each of the N435S , V447A , and L452 M mutations .	1 1 11 11 11 11 11 11 11 11 2 15 15 15 2|14|15 2|14|15 2|15 2|14|15 1 33 30 30 30 30 30 30 30 30 30 20 33 33 33 36 36 33 41 41 41 41 36 33 44 47 46 44 47 50 50 47 58 58 58 58 58 58 58 50 58 63 63 63 58 65 63|64 63 63|64 65 47 47 71 78 74 74 71 78 78 78 47 82 82 82 78 82 86 86 82 90 90 90 86 47 96 95 96 105 100 100 100 96 102 100|101 100 100|101 105 105 110 110 110 110 105 115 113 115 115 110 117 115 121 121 121 117 121 121 126 126 121 130 130 130 121 105 134 151 137 137 134 144 144 141 144 144 144 137 146 144|145 144 144|145 151 151 151 151 158 158 155 153 158 158 151 161 161 158 163 161 168 168 168 168 163 161 171 161 173 171 151 179 176|179 179 176|179 182 182 182 182 185 185 183|185|182 183|185|182 185|182 183|185|182 182 182 191 198 193 191 195 191|195 191|195 191|195 191|195 182 204 201 204 204 204 198 198 213 213 213 213 213 215 213 218 218 225 218 221 218 225|221 225|221 225 225|221 215 227 225 229 226|227 227 226|227 225 215 235 235 232 238 238 235 240 245 245 245 245 245 238 213 256 254 254 253 254 249 256 256 256 256 261 261 275 264 264 261 266 264 266 266 268 264 264 264 264 275 256 279 279 279 275 282 282 279 256 285 287 287 287 290 290 287 287 293 296 296 296 296 298 296 301 301 298 301 301 303 296 308 308 296 296	Association
15170666	Disease	Gene	D001943	5892	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ RAD51D @/GeneOrGeneProductTgt$ ? [SEP] The variant E233 G of the @GeneOrGeneProductTgt$ RAD51D @/GeneOrGeneProductTgt$ gene could be a low-penetrance allele in high-risk @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ families without BRCA1/2 mutations . Six SNPs have been detected in the DNA repair genes RAD51C and @GeneOrGeneProductTgt$ RAD51D @/GeneOrGeneProductTgt$ , not previously characterized . The novel variant E233 G in @GeneOrGeneProductTgt$ RAD51D @/GeneOrGeneProductTgt$ is more highly represented in high-risk , site-specific , @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases that are not associated with the BRCA1/2 genes , with a frequency of 5.74 % ( n = 174 ) compared to a control population ( n = 567 ) and another subset of @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ patients ( n = 765 ) with a prevalence of around 2 % only ( comparison to controls , OR = 2.6 , 95 % CI 1.12 - 6.03 ; p < 0.021 ) . We found that the immunohistochemical profile detected in available tumors from these patients differs slightly from those described in non-BRCA1/2 tumors . Finally , the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure . This suggests a role for E233 G as a low-penetrance susceptibility gene in the specific subgroup of high-risk @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases that are not related to BRCA1/2 .	4 4 4 14 9 9 9|6 9 9|6 4 14 14 14 14 14 20 20 20|15 20|15 20 20|15 14 23 23 20 14 28 31 31 31 31 36 36 36 36 31 36 37 37|38 37 37|38 36 44 44 36 31 51 51 51 51 58 53 51|52 51 51|52 58 57 58 58 68 68 60 60 60 62|64|68|60 62|64|68|60 62|64|68|60 64|68|60 62|64|68|60 58 72 72 72 68 76 76 76 72 68 80 80 58 83 83 80 85 86 83 86 86 80 93 93 93 89 96 96 93 96 96 93 101 93 106 98|106 98|106 106 98|106 101 108 106 108 109 108 114 114 93 118 117 118 114 121 121 118 123 121 58 126 58 131 131 130 131 126 134 134 131 137 137 131 137 58 58 145 145 157 149 149 157 149 153 153 150 156 156 153 145 157 160 157 160 164 164 161 145 179 179 170 170 179 175 175 175 175 170 178 178 175 179 183 183 183 179 183 184 185 185 179 190 190 192 190 195 195 192 200 200 200 200 192 204 204 204 200 211 211 206|211 206|211 206|211 211 206|211 204 215 215 215 211 217 215 190	Association
17550384	Disease	Gene	D001943	8678	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast carcinoma @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ ? [SEP] Somatic mutations of @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein is a key regulator of autophagic PCD . The @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene that encodes @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 @DiseaseOrPhenotypicFeatureSrc$ breast carcinomas @/DiseaseOrPhenotypicFeatureSrc$ , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one @DiseaseOrPhenotypicFeatureSrc$ breast carcinoma @/DiseaseOrPhenotypicFeatureSrc$ ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ . This is the first report on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 150 150|147 150|147 150|147 150|147 124 156 156 124 156 160 160 156 156 164 164 156 156 156 171 171 171 171 156 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 236 236|240|235 236|240|235 236|240 236|240|235 240 233 240 224 245 245 248 248 245 251 251 248 251 251 253 253 251 259 259 248 245 245 245 272 272 266 264 266 266 266 271 264 262 274 275 278 278 278 272 262 283 283 283 279|282 279 279|282 245 291 291 291 291 291 296 296|292 296 296|292 296 291 300 300 300 296 291 291 304 305 291 312 308 312 312 312 312 305 316 316 316 312 312 321 321 321 312 324 324 321 327 327 321 305	Association
17550384	Disease	Gene	D002289	8678	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ non-small cell lung cancers @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ ? [SEP] Somatic mutations of @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein is a key regulator of autophagic PCD . The @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene that encodes @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 breast carcinomas , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 @DiseaseOrPhenotypicFeatureSrc$ non-small cell lung cancers @/DiseaseOrPhenotypicFeatureSrc$ by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ . This is the first report on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 151 151 147 124 155 155 124 155 159 159 155 155 163 163 155 155 155 167 167|155|164 167|155|164 167|155|164 167|155|164 167|155 167|155|164 175 175 175 167 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 237 237 239 239 233 239 224 243 243 246 246 243 249 249 246 249 249 251 251 249 257 257 246 243 243 243 270 270 264 262 264 264 264 269 262 260 272 273 276 276 276 270 260 281 281 281 277|280 277 277|280 243 289 289 289 289 289 294 294|290 294 294|290 294 289 298 298 298 294 289 289 302 303 289 310 306 310 310 310 310 303 314 314 314 310 310 319 319 319 310 322 322 319 325 325 319 303	Association
17550384	Disease	Gene	D013274	8678	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ gastric carcinomas @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ ? [SEP] Somatic mutations of @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein is a key regulator of autophagic PCD . The @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene that encodes @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene for detection of somatic mutations in 180 @DiseaseOrPhenotypicFeatureSrc$ gastric carcinomas @/DiseaseOrPhenotypicFeatureSrc$ , 94 breast carcinomas , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ . This is the first report on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 146 146 143|146|140 143|146|140 146|140 143|146|140 146 152 152 146 124 156 156 124 156 160 160 156 156 164 164 156 156 156 171 171 171 171 156 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 237 237 239 239 233 239 224 243 243 246 246 243 249 249 246 249 249 251 251 249 257 257 246 243 243 243 270 270 264 262 264 264 264 269 262 260 272 273 276 276 276 270 260 281 281 281 277|280 277 277|280 243 289 289 289 289 289 294 294|290 294 294|290 294 289 298 298 298 294 289 289 302 303 289 310 306 310 310 310 310 303 314 314 314 310 310 319 319 319 310 322 322 319 325 325 319 303	Association
17550384	Disease	Gene	D015179	8678	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ colorectal @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ ? [SEP] Somatic mutations of @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein is a key regulator of autophagic PCD . The @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene that encodes @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 breast carcinomas , 50 acute leukemias , 50 @DiseaseOrPhenotypicFeatureSrc$ colorectal carcinomas @/DiseaseOrPhenotypicFeatureSrc$ , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three @DiseaseOrPhenotypicFeatureSrc$ colorectal @/DiseaseOrPhenotypicFeatureSrc$ , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ . This is the first report on @GeneOrGeneProductTgt$ BECN1 @/GeneOrGeneProductTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 151 151 147 124 155 155 124 155 158 158|155 158|155 158|155 158|155 155 164 164 155 155 155 171 171 171 171 155 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 229|227 227 229|227 230 234 230 234 238 238 240 240 234 240 224 245 245 248 248 245 251 251 248 251 251 253 253 251 259 259 248 245 245 245 272 272 266 264 266 266 266 271 264 262 274 275 278 278 278 272 262 283 283 283 279|282 279 279|282 245 291 291 291 291 291 296 296|292 296 296|292 296 291 300 300 300 296 291 291 304 305 291 312 308 312 312 312 312 305 316 316 316 312 312 321 321 321 312 324 324 321 327 327 321 305	Association
17889706	Disease	Gene	D001943	8994	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast tumors @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ LIMD1 @/GeneOrGeneProductTgt$ ? [SEP] Identification of rare variants in the @GeneOrGeneProductTgt$ hLIMD1 @/GeneOrGeneProductTgt$ gene in @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . The @GeneOrGeneProductTgt$ hLIMD1 @/GeneOrGeneProductTgt$ gene is located at chromosome 3p21 and was identified as a putative tumor suppressor gene using an elimination test assay . Chromosome 3p21 loci are frequently deleted in a number of cancers , including breast . The 3p21.3 locus harbors a number of tumor suppressor candidates , including @GeneOrGeneProductTgt$ LIMD1 @/GeneOrGeneProductTgt$ , a member of the ZYXIN family of genes . @GeneOrGeneProductTgt$ LIMD1 @/GeneOrGeneProductTgt$ directly interacts with RB and is thought to play a role in suppressing tumor growth . To investigate whether mutations in the @GeneOrGeneProductTgt$ LIMD1 @/GeneOrGeneProductTgt$ gene could potentially be involved in @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ , we used single-stranded conformation polymorphism analysis on DNA from 235 @DiseaseOrPhenotypicFeatureSrc$ breast cancers @/DiseaseOrPhenotypicFeatureSrc$ and 95 controls . We identified four novel coding region alterations , including two amino acid substitutions at positions 255 and 302 . The two remaining novel variants were found at amino acid positions 246 and 647 and encoded silent alterations . The rare Ser255Arg variant was identified in only sporadic @DiseaseOrPhenotypicFeatureSrc$ breast tumors @/DiseaseOrPhenotypicFeatureSrc$ ( 2/165 tumors ) . Some ZYXIN proteins are phosphorylated by serine/threonine kinases , and the Ser255Arg change is located in a region phosphorylated on serine residues . Together , the data suggest that this variant may warrant further characterization .	1 4 4 1 9 9 9|6 9 9|6 4 11 9|11 9|11 9|11 9|11 1 20 17|20 20 17|20 22 22 22 25 25 22 22 28 22 34 34 34 34 34 28 34 39 39 39 35 22 44 44 47 47 47 47 50 50 47 52 50 52 55 52 47 59 59 60 60 62 60 66 66 66 62 66 69 66|68 66 66|68 69 73 69 77 77 77 73 79 77 60 81|85 85 81|85 85 85 87 85 85 90 85 92 90 94 92 96 92 98 96 85 102 102 113 113 109 109 109|106 109 109|106 104 113 113 113 102 115 113|115 113|115 113|115 113|115 120 120 102 124 124 124 120 126 124 129 129 125|126|129 125|126|129 126|129 125|126|129 129 134 129 120 140 140 145 145 145 145 140 145 151 151 151 151 145 153 151 153 154 154 140 159 160 164 162 160 164 164 168 168 168 164 168 169 169 164 164 175 173 164 180 180 180 182 182 182 186 186 186 185|186|182 185|186|182 186|182 185|186|182 191 191 186 191 182 197 197 199 199 199 202 202 199 199 199 207 207 209 209 199 212 212 209 212 216 216 213 209 222 222 221 222 222 227 225 227 227 222 229 227 222	Association
16123141	Disease	Gene	D001943	26994	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ ? [SEP] Molecular characterization of @GeneOrGeneProductTgt$ ring finger protein 11 @/GeneOrGeneProductTgt$ . Ring finger proteins serve many vital functions within the cell . We have identified @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ , a novel 154-amino acid ring finger-containing protein , which is elevated in @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ . Within its ring finger domain , @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ contains an AKT phosphorylation site ( T135 ) that is situated within a 14 - 3 - 3 binding domain . In WM239 cells with constitutively active AKT , @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ exhibits seven distinct phosphopeptides as measured using two-dimensional phosphopeptide mapping . Upon inhibition of the AKT pathway or mutation of T135 , the phosphorylation at one of these sites is virtually eliminated , suggesting that AKT may phosphorylate @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ at T135 . Moreover , @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ is phosphorylated by AKT in vitro and is recognized by phospho-AKT substrate antibodies . @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ shows enhanced binding to 14 - 3 - 3 in WM239 cells compared with that seen in the parental WM35 cells which have low AKT activity . Furthermore , treatment of WM239 cells with LY294002 reduces @GeneOrGeneProductTgt$ RNF11/14 @/GeneOrGeneProductTgt$ - 3 - 3 interactions suggesting that @GeneOrGeneProductTgt$ RNF11/14 @/GeneOrGeneProductTgt$ - 3 - 3 binding is regulated by AKT . In addition , @GeneOrGeneProductTgt$ RNF11/14 @/GeneOrGeneProductTgt$ - 3 - 3 binding is enhanced by constitutively active AKT and is diminished by dominant-negative AKT . There is also reduced 14 - 3 - 3 binding to T135E @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ . @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ localization was altered from the cytoplasm to the nucleus by activated AKT . Thus , phosphorylation of @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ by AKT either causes its nuclear localization or induces degradation of cytoplasmic @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ . In addition , T135E @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ , which does not bind 14 - 3 - 3 and is not phosphorylated by AKT , causes a greater enhancement of transforming growth factor-beta signaling than wild-type @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ . It is clear that @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ function , localization , and potentially , degradation are regulated by AKT . Disregulation of proper @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ function by AKT may prove to be detrimental to patient outcomes , making @GeneOrGeneProductTgt$ RNF11 @/GeneOrGeneProductTgt$ a potential target for novel cancer therapeutics .	2 2 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 2 12 13 14 14 17 17 14 20 20 17 14 24 24 24 24 24 24 25 34 34 34 34 34 34 25 34 38 38 34 40 38|40 38|40 38|40 38|40 24 50 50 50 50 54 54 54|51 54 54|51 54 58 58 58 54 60 58 60 64 64 58 73 73 69 69 71 71 73 73 64 54 78 78 86 82 81 82 78 86 83|86 86 83|86 86 89 89 86 91 86 91 95 95 92 86 99 118 103 103 103 99 99 99 107 105 107 110 118 112 110 115 115 112 118 118 118 118 118 124 124 124 120 124 124 124 128 124 118 136 136 132|136 136 132|136 136 136 138 136 140 136 136 143 136 147 147 147 143 136 149|152 152 149|152 153 153 153 160 158 158 160 160 154 163 163 154 166 166 154 166 172 172 172 172 167 174 172 177 177 174 153 188 188 188 185 185 182 187 182 188 188|194 194 188|194 192 194 194 195 188 195 206 196|201 201 196|201 201 204 203 201 206 206 196 208 206 188 213 223 223 214|218 218 214|218 218 221 220 218 223 223 223 227 226 227 223 223 230 223 233 233 230 223 239 239 239 239 242 242 244 244 245 248 247 245 247|239 239 247|239 239 251|254 254 251|254 256 256 256 259 259 256 262 262 259 265 265 256 256 277 277 277 272 270|271 270 270|271 275 270 270 277 280 280 277 277 277 282 285 286 283|284 283 283|284 277 292 314 314 295 314|294 314 314|294 295 301 301 301 295 304 304 306 304 301 301 310 310 301 312 310 314 314 317 317 314 322 322 322 322 317 325 325 322|323 322 322|323 314 331 331 331 345 345|333 345 345|333 334 336 336 338 336 336 345 345 345 332 347 345 331 359 355 355 352|355 355 352|355 350 357 350 359 359 362 362 359 364 362 364 362 362 366|372 372 366|372 372 372 367 376 376 376 372 359	Association
17531442	Disease	Gene	D001943	672	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ MCF-7 breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ ? [SEP] Identification of sequences that target @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ to nuclear foci following alkylative DNA damage . @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ is a tumor suppressor involved in the maintenance of genome integrity . @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ co-localizes with DNA repair proteins at nuclear foci in response to DNA double-strand breaks caused by ionizing radiation ( IR ) . The response of @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ to agents that elicit DNA single-strand breaks ( SSB ) is poorly defined . In this study , we compared chemicals that induce SSB repair and observed the most striking nuclear redistribution of @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ following treatment with the alkylating agent methyl methanethiosulfonate ( MMTS ) . In @DiseaseOrPhenotypicFeatureSrc$ MCF-7 breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cells , MMTS induced movement of endogenous @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ into distinctive nuclear foci that co-stained with the SSB repair protein XRCC1 , but not the DSB repair protein gamma-H2AX . XRCC1 did not accumulate in foci after ionizing radiation . Moreover , we showed by deletion mapping that different sequences target @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ to nuclear foci induced by MMTS or by ionizing radiation . We identified two core MMTS-responsive sequences in @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ : the N-terminal BARD1-binding domain ( aa1 - 304 ) and the C-terminal sequence aa1078 - 1312 . These sequences individually are ineffective , but together they facilitated @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ localization at MMTS-induced foci . Site-directed mutagenesis of two SQ/TQ motif serines ( S1143A and S1280A ) in the @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ fusion protein reduced , but did not abolish , targeting to MMTS-inducible foci . This is the first report to describe co-localization of @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ with XRCC1 at SSB repair foci . Our results indicate that @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ requires BARD1 for targeting to different types of DNA lesion , and that distinct C-terminal sequences mediate selective recruitment to sites of double- or single-strand DNA damage .	1 3 1 5 3 5 5 5 10 10 5 14 14 14 5 1 16|22 22 16|22 22 22 22 22 22 26 26 23 29 29 26 22 31|34 34 31|34 34 38 38 38 34 41 41 34 43 34 47 47 47 43 47 51 51 48 53 51 53 34 58 74 60 58|59 58 58|59 63 58 65 63 68 68 65 70 68 70 74 74 74 74 79 79 82 82 82 82 82 85 83 87 85 85 85 94 92 94 94 89 96 94|95 94 94|95 99 94 105 105 103 105 105 99 107 105 107 82 116 111|116 111|116 111|116 116 111|116 119 119 119 119 119 123 123 119|120 120 119|120 128 128 128 120 130 128 136 136 136 136 136 130 136 139 136 144 144 144 144 136 119 151 151 151 151 153 151 156 156 153 151 161 161 161 161 164 164 161 168 167 168 164 168 168 168 173 173 168 173 176 174 176 180 180 176 161 184 184 188 188 188 184 190 188|189 188 188|189 188 196 196 196 188 198 196 198 198 198 196 206 206 206 196 206 206 184 212 215 215 215 215 215 215 220 220 215 220|223 223 220|223 220 226 226 220 220 230 247 235 235 235 235 230 237 235 237 237 237 246 246 246|242 246 246|242 246 235 247 247 247 252 252 247 252 252 257 257 254 247 264 264 264 264 264 266 264 266 269 267|268 267 267|268 272 267 276 276 276 267 264 280 281 281 285 282|285 285 282|285 281 285 288 285 291 291 288 294 294 291 285 285 301 300 300 301 285 303 301 305 303 307 311 307 307 311 303 281	Association
12645254	Disease	Gene	D001943	672	True	0	What is [Litcoin] between @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ and @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ ? [SEP] [ Studies of mutations in @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ transactivation domain by visualization of chromatin structure ] . Mutations in @DiseaseOrPhenotypicFeatureSrc$ breast cancer @/DiseaseOrPhenotypicFeatureSrc$ susceptibility gene @GeneOrGeneProductTgt$ 1(BRCA1 @/GeneOrGeneProductTgt$ ) account for approximately 40%-50 % of @DiseaseOrPhenotypicFeatureSrc$ familial breast cancer @/DiseaseOrPhenotypicFeatureSrc$ cases and for more than 80 % of inherited breast and ovarian cancer cases . Many cancer-predisposing mutations are located in the C-terminal region that functions as a transcriptional activation domain , but most of the mutations in the transactivation domain identified to date can not be readily distinguished as either disease-associated mutations or benign polymorphisms . Because chromatin structure regulation is an early event in gene transcription control , the chromatin unfolding activities of different transactivation domain variants were compared with that of the wild-type transactivation domain by use of an approach that allows visualization of large-scale chromatin structure through lac repressor/lac operator recognition . To do this , different constructs of the transactivation domain were selected as follows : ( a ) the wild-type transactivation domain ; ( b ) two polymorphisms ( S1613 G and M1652I ) ; and ( c ) four cancer-predisposing mutations ( A1708E , M1775R , W1837R and Y1853 term ) . All of the constructs were made by fusing in frame with lac repressor . Western blot analysis indicated that all of the fusion proteins were expressed in A03 1 cells , in which multiple copies of the lac operator were integrated to produce a heterochromatic region of the genome . The chromatin unfolding assay showed that , like the wild-type transactivation domain , two variants that represent benign polymorphisms did not induce chromatin unfolding or only induced subtle change . Contrary to the behaviors of the wild type and two benign variants , four cancer-predisposing mutations in the transactivation domain superactivate the chromatin unfolding . The results suggest that the chromatin unfolding assay can aid in the characterization of deterious mutations in the C-terminal transactivation domain of @GeneOrGeneProductTgt$ BRCA1 @/GeneOrGeneProductTgt$ and may provide more reliable presymptomatic risk assessment .	2 2 4 2 9 9|5 9 9|5 9 4 11 2 14 14 11 2 2 28 24 19|24 19|24 24 19|24 24 25 18|22 18 18|22 25 28 32 31 32 28 38 38|30 38|30 38|30 38 38|30 32 32 44 43 43 44 32 47 47 44 47 47 51 47 28 58 58 60 60 60 64 64 64 60 66 64 71 71 71 71 66 60 60 82 77 77 74 81 81 81 77 60 84 82 89 89 89 89 60 93 93 93 89 93 96 93 60 105 101 101 105 105 105 105 121 109 109 109 105 121 114 114 114 121 119 119 119 119 114 121 121 123 121 128 128 128 128 123 130 121 133 133 130 135 133 135 140 140 140 136 145 145 145 145 136 121 148 158 148 152 152 158 156 156 156 152 158 158 160 158 160 163 168 163 168 168 168 158 168 171 174 171 174 168 177 177 174 177 177 177 174 168 184 188 188 188 188 168 190 188 190 190 190 190 190 190 190 190 158 205 203 203 200 205 205 207 205 209 207 212 212 209 205 216 216 217 217 225 225 223 223 223 219 225 217 229 229 229 225 229 232 240 234 240 238 238 238 234 240 229 242 240 245 245 242 248 248 245 217 253 253 253 254 254 271 271 261 261 261 261 271 271 264 271 266 264 268 266 271 271 254 273 271 271 276 271 278 276 254 300 283 283 280 287 287 287 283 287 291 291 287 300 295 295 300 299 299 299 295 300 303 303 300 300 306 307 307 314 312 312 312 314 314 307 317 317 314 320 320 317 325 325 325 325 320 327 325|326 325 325|326 314 331 314 333 336 336 336 331 307	Association
